港股異動 | 亞盛醫藥-B盤中漲超10% 3日連漲30%走出反轉行情
格隆匯2月1日丨亞盛醫藥-B(6855.HK)盤中繼續拉昇漲超10%,近3個交易日大漲超30%走出反轉行情,最高報33.15港元創14個月新高價,總市值85億港元。消息上,去年亞盛醫藥自主研發的奧雷巴替尼(耐立克®)已獲批上市,身為國內首個且唯一獲批上市的第三代BCR-ABL靶向耐藥CML治療藥物,奧雷巴替尼以合理價格成功納入2022版國家醫保藥品目錄。有分析稱,奧雷巴替尼的談判價格被視為遠超市場預期,後續銷售或將迎來放量增長。公司在小分子創新藥領域中有着不可或缺的地位,已獲得許多投資者的關注和認可。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.